Bivalirudin - Eagle Pharmaceuticals

Drug Profile

Bivalirudin - Eagle Pharmaceuticals

Alternative Names: Bivalirudin RTU; EP-6101; Kangio; Ready-to-use bivalirudin; RTU bivalirudin

Latest Information Update: 27 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Heparin-induced thrombocytopenia and thrombosis syndrome; Unstable angina pectoris

Most Recent Events

  • 15 Mar 2017 Eagle pharmaceuticals and The Medicines company has patent protection for bivalirudin in USA
  • 15 Mar 2017 Eagle pharmaceuticals and The Medicines company has patent pending for bivalirudin in USA
  • 15 Mar 2017 The Medicines company initiates litigation against SciDose and TherDose Pharma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top